AMZN.NASDAQAmazon Com INC

13F-HR: Amazon's Q1 2026 Holdings Report

Sentiment:

Quarterly Holdings Report


Amazon.com Inc. discloses its Q1 2026 equity holdings, revealing a significant investment in Rivian Automotive Inc. and other tech companies.

Summary

  • Amazon.com Inc. has filed its Form 13F for the quarter ended March 31, 2026.
  • The filing reports a total of 5 distinct holdings.
  • The total value of these holdings amounts to $2,631,514,371.
  • The primary investment is in Rivian Automotive Inc. (COM CL A) with a value of $2,383,375,702.
  • Other reported holdings include Asterra Labs Inc. (COM), Beta Technologies Inc. (COM SHS CL A), Marvell Technology Inc. (COM), and Nautilus Biotechnology Inc. (COM).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of existing holdings without new strategic announcements or performance data.

Positives

  • Amazon.com Inc. maintains a diverse portfolio of technology-focused investments.
  • The company holds a substantial position in Rivian Automotive Inc., indicating confidence in its future prospects.
  • All reported holdings are managed solely by Amazon, suggesting clear investment strategy and control.

Negatives

  • The filing does not provide performance data for the reported holdings, making it difficult to assess profitability.
  • A significant portion of the total reported value is concentrated in a single company (Rivian Automotive Inc.), which could represent a concentration risk.

Risks

  • The substantial investment in Rivian Automotive Inc. exposes Amazon to the specific market and operational risks associated with the electric vehicle industry.
  • Fluctuations in the stock prices of Asterra Labs Inc., Beta Technologies Inc., Marvell Technology Inc., and Nautilus Biotechnology Inc. could impact the overall value of Amazon's portfolio.
  • The concentration of assets in a few technology companies carries inherent market volatility risks.

Future Outlook

This filing is a historical report of holdings as of a specific date and does not contain forward-looking statements or guidance from Amazon regarding its investment strategy.

Industry Context

StockSavvy.ai notes that this 13F filing from Amazon.com Inc. reflects a common practice among large institutional investors to disclose their equity holdings quarterly. The significant investment in Rivian Automotive Inc. aligns with broader trends of major tech companies diversifying into emerging sectors like electric vehicles and advanced technologies, though it also highlights the inherent risks of such concentrated bets.

Comparison to Industry Standards

  • The total reported value of $2.63 billion places Amazon's disclosed holdings within the range of large institutional investment portfolios.
  • The concentration in Rivian Automotive Inc. (approximately 90.5% of the total reported value) is notably higher than the average portfolio concentration seen in many diversified mutual funds or pension funds, which typically aim for broader diversification across sectors and asset classes.
  • Competitors like Apple and Microsoft also file 13F reports, and their portfolio compositions can be compared to identify differing strategic investment priorities in technology and related industries.

Stakeholder Impact

  • Shareholders: The value of Amazon's investment portfolio directly impacts its overall financial health and potential for investment gains.
  • Investors in Rivian Automotive Inc.: Amazon's significant stake can influence market dynamics and investor sentiment for Rivian.

Next Steps

  • Monitor future 13F filings from Amazon.com Inc. to observe changes in its investment portfolio.
  • Track the performance of Rivian Automotive Inc. and other disclosed holdings to assess the impact on Amazon's overall investment value.

Key Dates

DateDescription
2026-03-31Quarter End Date for the Report
2026-05-05Date of Signing

Keywords

Form 13F, Amazon, Rivian Automotive, Investment Holdings, SEC Filing, Equity Portfolio, Asterra Labs, Beta Technologies, Marvell Technology, Nautilus Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.